Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesInvolvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms
Leukemia, 04/27/09
Wang J et al. - Erlotinib, a JAK2 inhibitor, was able to inhibit JAK2V617F-positive PV MC progenitor cells, indicating that malignant MC progenitor cells are a potential cellular target for such JAK2 inhibitor-directed therapy.
Related Articles
Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms
British Journal of Haematology, 11/11/09
Relevance Score: 67%
AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms
Blood, 11/09/09
Relevance Score: 67%
Co-treatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplasm cells
Blood, 11/02/09
Relevance Score: 66%
Combined Inhibition of Janus Kinase 1/2 for the Treatment of JAK2V617F-Driven Neoplasms: Selective Effects on Mutant Cells and Improvements in Measures of Disease Severity
Clinical Cancer Research, 11/09/09
Relevance Score: 65%
Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type
Annals of Oncology, 10/29/09
Relevance Score: 44%
Today in Myeloproliferative Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia
Journal of Clinical Oncology, 12/20/09
Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma
Cancer Research, 12/20/09
Telomere shortening and chromosomal instability in myelodysplastic syndromes
Genes, Chromosomes and Cancer, 12/20/09
Sponsor
Article Search
Sponsor
Sponsor